Overview
- 9 FDA inspections are on record.
- 4 inspections produced a Form 483.
- The most recent recorded inspection date is 2026-05-08.
At a glance
Inspections
9
Form 483s
4
EIRs
0
Last outcome
Form 483
Inspection history
FDA inspections on record, most recent first.
| Inspection | Category | Outcome | Form 483 |
|---|---|---|---|
| 4 May 2026 – 8 May 2026 | Human Drugs | 483 | On file |
| 15 Jul 2024 – 19 Jul 2024 | Human Drugs | 483 | On file |
| 12 Jul 2021 – 14 Jul 2021 | Human Drugs | Clean | |
| 31 Mar 2014 – 3 Apr 2014 | Human Drugs | Clean | |
| 5 Oct 2012 | Not recorded | Clean | |
| 14 Jun 2012 | Not recorded | 483 | View 483 → |
| 11 Dec 2009 | Not recorded | Clean | |
| 29 Sep 2009 | Not recorded | 483 | View 483 → |
| 16 Oct 2008 | Not recorded | Clean |
Observations on record
Form 483 observations cited at this site, most recent first.
14 Jun 2012
21 CFR 211.192
Investigations of discrepancies, failures
Cited by Debra M Emerson, Mary-Jeanet Mcgarry
14 Jun 2012
21 CFR 314.81(b)(1)(ii)
Contamination, chemical or physical change, deterioration
Cited by Debra M Emerson, Mary-Jeanet Mcgarry
29 Sep 2009
21 CFR 211.25(a)
Training--operations, GMPs, written procedures
Cited by Debra M Emerson, Stacey S Degarmo
29 Sep 2009
21 CFR 211.186(b)(8)
Description of containers, labels, et. al.
Cited by Debra M Emerson, Stacey S Degarmo
29 Sep 2009
21 CFR 314.80(b)
Failure to develop written procedures
Cited by Debra M Emerson, Stacey S Degarmo
Investigators
FDA investigators tied to this site in the record.
Mary-Jeanet Mcgarry2 insp.
Debra M Emerson2 insp.
Lori M Newman1 insp.
Kent A Conforti1 insp.
Kara A Scheibner1 insp.
Sylvestre K Dossou1 insp.
Sean R Marcsisin1 insp.
Stephen J Mottola1 insp.
Robert J Martin1 insp.
Stacey S Degarmo1 insp.
Kenneth H Williams1 insp.
Paraluman S Leonin1 insp.
Recurring citations
CFR citation patterns observed across this site's inspections.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.186(b)(8) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.25(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.80(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.80(c) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.80(c)(2) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.81(b)(1)(i) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.81(b)(1)(ii) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.81(b)(2) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.81(b)(2)(i) | Cited across public-safe Form 483 observations | 1x |
Full site report
Get the verbatim findings behind Armstrong Pharmaceuticals, Inc.'s 4 Form 483s
Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.
- The site's full inspection history, with every Form 483 and its outcome
- Warning letters and recalls tied to the company behind it
- Whether recurring CFR citations get closed out or repeat